Search results for "DEXA"

showing 10 items of 264 documents

In vitro antibacterial activity of endodontic sealers

2004

Summary Objectives To evaluate the antibacterial activity of four endodontic sealers: one epoxy resin sealer (AH Plus), two zinc oxide eugenol (ZOE)-based sealers (Endomethasone, Pulp Canal Sealer), and one sealer containing both ZOE and orthophenilphenol (Vcanalare). Methods A direct contact test (DCT) was performed. A 10 μl suspension of Enterococcus faecalis was placed on the test material 20 min, 24 h and 7 days after mixing. Bacteria were allowed to directly contact the sealers for 1 h at 37 °C. Bacterial growth was then spectrophotometrically measured every 30 min for 7 h, and again after 24 h as well. Results All freshly mixed sealers showed complete inhibition of bacterial growth. S…

Settore MED/07 - Microbiologia E Microbiologia ClinicaContact testTime FactorsMaterials scienceHydrocortisoneDentistryBacterial growthDexamethasoneEnterococcus faecalisRoot Canal Filling Materialschemistry.chemical_compoundSettore MED/28 - Malattie OdontostomatologicheFormaldehydeEnterococcus faecalisPulp canalGeneral DentistrybiologyEpoxy Resinsbusiness.industryEndodontic sealerbiology.organism_classificationAntimicrobialThymolIn vitroAnti-Bacterial AgentsDrug CombinationschemistryZinc oxide eugenolDirect contact testDrug EvaluationAntibacterial activityEnterococcus faecaliAntibacterial activitybusinessNuclear chemistryJournal of Dentistry
researchProduct

BONE LOSS I INFLAMMATORI BOWEL DISEASE: OUR MULTICENTRIC STUDY

2011

Patients with inflammatory bowel disease are at increased risk of developing disorder in bone and mineral metabolism. The study was aimed to determine if inflammatory bowel disease (IBD) is a risk factor for osteoporosis in 103 adult patients. We included 103 IBD patients, 67 patients with Crohn's disease (CD) and 36 with ulcerative colitisi (UC). Bone mineral density was measured by dual-energy X-ray absorptiometry. we used T score to express bone loss (osteopenia: -25SD 2 years) and active disease would be risk of bone mineral loss in IBD.

Settore MED/18 - Chirurgia GeneraleCrohn's disease Osteoporosis dexa inflammatory bowel disease ulcerative colitis.
researchProduct

Intratympanic treatment with dexamethasone as first-line or salvage therapy in sudden sensorineural hearing loss: Results of a retrospective study

2014

Aim: Sudden sensorineural hearing loss is a condition of emergency in Otolaryngology. Although there is no universally accepted treatment protocol, corticosteroids, intravenous and oral, are the most common treatment The purpose of this study is to evaluate the efficacy of intratympanic administration of dexamethasone as first line therapy, or as a rescue therapy after treatment with systemic steroids in patients not responders. Methods: The population, consisting of 85 patients referred to our unit from January 2010 to December 2013, was divided into two groups according to the treatment protocol performed. We also analyzed possible variables that may affect the response to treatment such …

Settore MED/31 - OtorinolaringoiatriaAudiometryOtorhinolaryngology2734 Pathology and Forensic MedicineHearing loSteroidDexamethasonePure-toneDexamethasonesudden hearing lossintratympanic treatment
researchProduct

Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation.

2000

Many in vitro studies have used cell cultures to focus on the relationships between cyclo-oxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) isoforms. We have investigated the time-course of regulation and the role of COX-2 and iNOS in a model of experimental inflammation in mice, the air pouch injected with zymosan. This study demonstrates that there is an early acute phase (4 h) mediated mainly by eicosanoids, with high levels of prostaglandin E2 (PGE2) produced by cyclo-oxygenase-1. In addition, in the later phase (from 12 h) there is a participation of nitric oxide (NO) and PGE2 accompanied by co-induction of both iNOS and COX-2. These enzymes were detected in migrating leuk…

Time FactorsBlotting WesternAnti-Inflammatory AgentsFluorescent Antibody TechniqueNitric Oxide Synthase Type IIInflammationPharmacologyDexamethasoneDinoprostoneNitric oxidechemistry.chemical_compoundMiceIn vivomedicineLeukocytesAnimalsCyclooxygenase InhibitorsProstaglandin E2NitritePharmacologyInflammationbiologyCyclooxygenase 2 InhibitorsZymosanZymosanGeneral MedicineExudates and TransudatesNitric oxide synthaseIsoenzymeschemistryBiochemistryCell cultureCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme Inductionbiology.proteinEicosanoidsFemalemedicine.symptomNitric Oxide SynthaseColchicinemedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Glucocorticoid receptor regulates organic cation transporter 1 (OCT1, SLC22A1) expression via HNF4α upregulation in primary human hepatocytes

2013

Abstract Background Organic cation transporter 1 (OCT1, SLC22A1) is a membrane transporter that is important for therapeutic effect of the antidiabetic drug metformin. Its liver-specific expression in hepatocytes is strongly controlled by hepatocyte nuclear factor-4α (HNF4α). HNF4α expression and transcriptional activity have been demonstrated to be augmented by glucocorticoid receptor (GR) in human hepatocytes and rodent livers. Methods It was examined whether GR activation indirectly induces OCT1 gene expression via HNF4α up-regulation in primary human hepatocytes.We also examined which other transcription factors are involved in OCT1 gene expression and whether they are regulated by dexa…

Time FactorsPrimary Cell CultureTransfectionDexamethasoneReceptors GlucocorticoidGlucocorticoid receptorTransduction GeneticEnhancer bindingCoactivatorGene expressionHumansRNA MessengerGlucocorticoidsTranscription factorPharmacologyRegulation of gene expressionChemistryCCAAT-Enhancer-Binding Protein-betaOrganic Cation Transporter 1Hep G2 CellsGeneral MedicineTransfectionPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMolecular biologyUp-RegulationHepatocyte Nuclear Factor 4Cell cultureHepatocytesTranscription FactorsPharmacological Reports
researchProduct

Effectiveness of early administration of a single dose of steroids and escin after loss of signal on electromyographic signal recovery during neuromo…

2022

Background: The aim of this study was to evaluate the effect of a single early administration of dexamethasone and escin after loss of signal (LOS) during a neuromonitored total thyroidectomy. Methods: A retrospective analysis of results concerning consecutive patients undergoing total thyroidectomy was performed. Patients included in the study were divided into two groups: Group 1 for which a “wait and see” strategy was used; Group 2, receiving dexamethasone and escin immediately after LOS detection. Results: Overall 37 patients were included in Group 1 and 35 in Group 2. LOS recovery occurring in 29.7% of cases (n. 11) versus 65.7% (n. 23) respectively (p < 0.001). Postoperative fibrol…

Total thyroidectomyEscinStaged thyroidectomyCordbusiness.industrymedicine.medical_treatmentThyroidectomyGeneral MedicineSignal onDexamethasoneLoss of signalSignal recoveryAnesthesiaThyroidectomyRetrospective analysisHumansMedicineSteroidsSurgerybusinessSteroidDexamethasoneRetrospective Studiesmedicine.drugThe American Journal of Surgery
researchProduct

Dexamethasone Inhibits the Pro-Angiogenic Potential of Primary Human Myoblasts

2021

Tissue regeneration depends on the complex processes of angiogenesis, inflammation and wound healing. Regarding muscle tissue, glucocorticoids (GCs) inhibit pro-inflammatory signalling and angiogenesis and lead to muscle atrophy. Our hypothesis is that the synthetic GC dexamethasone (dex) impairs angiogenesis leading to muscle atrophy or inhibited muscle regeneration. Therefore, this study aims to elucidate the effect of dexamethasone on HUVECs under different conditions in mono- and co-culture with myoblasts to evaluate growth behavior and dex impact with regard to muscle atrophy and muscle regeneration. Viability assays, qPCR, immunofluorescence as well as ELISAs were performed on HUVECs,…

Vascular Endothelial Growth Factor A0301 basic medicineMuscle tissueCD31endocrine systemQH301-705.5AngiogenesisMyoblasts SkeletalNeovascularization PhysiologicInflammationdexamethasonehuman primary myoblastsArticleCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineHuman Umbilical Vein Endothelial Cellsmedicinepolycyclic compoundsHumansMyocyteBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopyHUVECsTube formationChemistryOrganic ChemistryGeneral Medicineco-cultureVEGFCoculture TechniquesMuscle atrophyComputer Science ApplicationsCell biologyChemistry030104 developmental biologymedicine.anatomical_structureGene Expression RegulationCD31medicine.symptomWound healing030217 neurology & neurosurgeryhormones hormone substitutes and hormone antagonistsInternational Journal of Molecular Sciences
researchProduct

Intravitreal dexamethasone implant versus anti-vascular endothelial growth factor therapy combined with cataract surgery in patients with diabetic ma…

2021

Objective: to compare outcomes of cataract surgery combined with either anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy or dexamethasone implant (DEX) in patients with diabetic macular oedema (DMO). Methods: Pubmed and Embase databases were searched for studies reporting outcomes of diabetic cataract surgery combined with either anti-VEGF or DEX, with a follow-up ≥3 months. The primary outcome was the mean change in central macular thickness (CMT). Mean change in best corrected visual acuity (BCVA) was considered as a secondary outcome. The mean difference between baseline and post-treatment values (MD) with 95%-Confidence Interval (95%CI) was calculated and meta-analyses were p…

Vascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresmedicine.medical_treatmentVisual AcuityEndothelial Growth FactorsMacular EdemaDexamethasoneCataractOphthalmologyDiabetes MellitusHumansMedicineIn patientDexamethasoneDiabetic Retinopathybusiness.industryDEXcataract surgeryCataract surgeryDiabetic cataractBevacizumabOphthalmologyAnti–vascular endothelial growth factor therapyDiabetic macular oedemaanti-VEGFdiabetic macular oedemaMeta-analysissense organsImplantbusinessmedicine.drugEye
researchProduct

Hyaluronan alkyl derivatives-based electrospun membranes for potential guided bone regeneration: Fabrication, characterization and in vitro osteoindu…

2020

Item does not contain fulltext The aim of the work was to determine the effects of the chemical functionalization of hyaluronic acid (HA) with pendant aliphatic tails at different lengths and free amino groups in terms of chemical reactivity, degradation rate, drug-eluting features, and surface properties when processed as electrospun membranes (EM) evaluating the osteoinductive potential for a possible application as guided bone regeneration (GBR). To this end, a series of HA derivatives with different aliphatic tails (DD-Cx mol% ≈ 12.0 mol%) and decreasing derivatization of free amino groups (DD(EDA) mol% from 70.0 to 30.0 mol%) were first synthesized, namely Hn. Then dexamethasone-loaded…

Whole membraneBone RegenerationDexamethasone; Electrospun nanofibers; GBR membranes; Hyaluronic acid alkylated.Nanofibers02 engineering and technologyHyaluronic acid alkylated01 natural sciencesPolyvinyl alcoholDexamethasoneGBR membranesHydrolysischemistry.chemical_compoundColloid and Surface ChemistryOsteogenesis0103 physical sciencesPhysical and Theoretical ChemistryHyaluronic AcidBone regenerationAlkylchemistry.chemical_classificationAqueous solutionMembranesElectrospun nanofibers010304 chemical physicsCyclodextrinMembranes ArtificialSurfaces and InterfacesGeneral Medicine021001 nanoscience & nanotechnologyReconstructive and regenerative medicine Radboud Institute for Molecular Life Sciences [Radboudumc 10]Membranechemistry0210 nano-technologyBiotechnologyNuclear chemistry
researchProduct

Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is…

2006

BACKGROUND AND OBJECTIVES: This European Group for Blood and Marrow Transplantation (EBMT) multicentre randomized phase III study was designed to assess the safety and efficacy of CD34+ selection in newly diagnosed myeloma patients undergoing autologous transplantation. DESIGN AND METHODS: One hundred and eleven patients responsive to initial chemotherapy were randomized to receive CD34+ selected (arm A) or unselected PBPC (arm B) after conditioning with high-dose melphalan and TBI. ASO-PCR was used to assess purging efficacy and reinfused tumor load. Tumor load could be assessed in 59 patients. RESULTS: CD34+ selection gave a median tumor cell depletion of 2.2 logs (0.77-5.96). No tumor ce…

autologous transplantMelphalanOncologyAdultMaleRiskmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentAntigens CD34Transplantation AutologousDexamethasoneDisease-Free SurvivalPostoperative ComplicationsRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineEuropean Group for Blood and Marrow TransplantatioAutologous transplantationHumansSurvival rateSurvival analysisMultiple myelomaAgedChemotherapyPeripheral Blood Stem Cell TransplantationHematologybusiness.industryBone Marrow PurgingHematologyCD34+ selectionMiddle Agedmedicine.diseasePrognosisSurvival AnalysisBone marrow purgingSurgerySurvival RateTreatment OutcomeDoxorubicinVincristineFemalebusinessMultiple Myelomamedicine.drugFollow-Up StudiesHaematologica
researchProduct